{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T16:31:06Z","timestamp":1778949066608,"version":"3.51.4"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1097\/mpa.0b013e31815ac538","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T14:54:25Z","timestamp":1236264865000},"page":"173-177","source":"Crossref","is-referenced-by-count":11,"title":["Significant Down-Regulation of the Plasminogen Activator Inhibitor 1 mRNA in Pancreatic Cancer"],"prefix":"10.1097","volume":"36","author":[{"given":"Ute","family":"Warnecke-Eberz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus L.","family":"Prenzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan E.","family":"Baldus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Metzger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans P.","family":"Dienes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elfriede","family":"Bollschweiler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnulf H.","family":"Hoelscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-11-20210212","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/canjclin.53.1.5","article-title":"J Cancer Statistics 2003.","volume":"53","author":"Jemal","year":"2003","journal-title":"CA Cancer J Clin"},{"key":"R2-11-20210212","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/ijc.2910570605","article-title":"Trends in pancreatic cancer mortality in Europe, 1955-1989.","volume":"57","author":"Fernandez","year":"1994","journal-title":"Int J Cancer"},{"key":"R4-11-20210212","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/00000658-199709000-00004","article-title":"Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications and outcomes.","volume":"226","author":"Yeo","year":"1997","journal-title":"Ann Surg"},{"key":"R5-11-20210212","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1572-0241.2000.01699.x","article-title":"A multispecialty approach to the diagnosis and management of pancreatic cancer.","volume":"95","author":"Hawes","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R6-11-20210212","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/bjs.1800820137","article-title":"Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study.","volume":"82","author":"Bramhall","year":"1995","journal-title":"Br J Surg"},{"key":"R7-11-20210212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1072-7515(99)00075-7","article-title":"Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database.","volume":"189","author":"Sener","year":"1990","journal-title":"J Am Coll Surg"},{"key":"R8-11-20210212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0960-7404(01)00016-0","article-title":"Molecular pathogenesis of pancreatic ductal adenocarcinoma and clinical implications.","volume":"10","author":"Magee","year":"2001","journal-title":"Surg Oncol"},{"key":"R9-11-20210212","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3322\/canjclin.51.1.15","article-title":"Cancer statistics 2001.","volume":"51","author":"Greenlee","year":"2001","journal-title":"CA Cancer J Clin"},{"key":"R10-11-20210212","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1097\/00000658-200112000-00007","article-title":"Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and\/or chemotherapy in the ESPAC-1 randomized controlled trial.","volume":"234","author":"Neoptolemos","year":"2001","journal-title":"Ann Surg"},{"key":"R11-11-20210212","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S1091-255X(00)80105-5","article-title":"Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators.","volume":"4","author":"Sohn","year":"2000","journal-title":"J Gastrointestinal Surg"},{"key":"R13-11-20210212","first-page":"33","article-title":"Patterns of failure after pancreaticoduodenectomy for ampullary carcinoma.","volume":"176","author":"Willett","year":"1993","journal-title":"Surg Gynecol Obstet"},{"key":"R14-11-20210212","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3748\/wjg.v12.i3.437","article-title":"Differential c-erbB-1 and c-erbB-2 expression in pancreatic and ampullary cancer.","volume":"12","author":"Prenzel","year":"2006","journal-title":"World J Gastroenterol"},{"key":"R15-11-20210212","first-page":"1397","article-title":"Significant overexpression of SPARC\/osteonectin mRNA in pancreatic cancer compared to cancer of the papilla of Vater.","volume":"15","author":"Prenzel","year":"2006","journal-title":"Oncol Rep"},{"key":"R16-11-20210212","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nrm977","article-title":"uPAR: a versatile signalling orchestrator.","volume":"3","author":"Blasi","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R17-11-20210212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z","article-title":"The urokinase-type plasminogen activator system in cancer metastasis: a review.","volume":"72","author":"Andreasen","year":"1997","journal-title":"Int J Cancer"},{"key":"R18-11-20210212","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/01.blo0000093845.72468.bd","article-title":"Urokinase plasminogen activator system.","volume":"425S","author":"Choong","year":"2003","journal-title":"Clin Orthop Relat Res"},{"key":"R19-11-20210212","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1160\/TH05-01-0054","article-title":"Plasminogen activation and cancer.","volume":"93","author":"Dano","year":"2005","journal-title":"Thromb Haemost"},{"key":"R20-11-20210212","first-page":"4945","article-title":"SERPINE2 (protease nexin I) promotes extracellular matrix production and local invasion of pancreatic tumors in vivo.","volume":"63","author":"Buchholz","year":"2003","journal-title":"Cancer Res"},{"key":"R21-11-20210212","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1158\/1078-0432.CCR-03-0079","article-title":"High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer.","volume":"10","author":"Warnecke-Eberz","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R22-11-20210212","first-page":"1241","article-title":"Overexpression of survivin mRNA is associated with a favourable prognosis following neoadjuvant radiochemotherapy in esophageal cancer.","volume":"13","author":"Warnecke-Eberz","year":"2005","journal-title":"Oncol Rep"},{"key":"R23-11-20210212","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1191\/0962280202sm286ra","article-title":"Partitioning and peeling for constructing prognostic groups.","volume":"11","author":"LeBlanc","year":"2002","journal-title":"Stat Methods Med Res"},{"key":"R24-11-20210212","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"R25-11-20210212","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration.","volume":"50","author":"Mantel","year":"1966","journal-title":"Chemother Rep"},{"key":"R26-11-20210212","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1055\/s-0037-1613396","article-title":"Posttranscriptional regulation of PAI-1 gene expression.","volume":"89","author":"Heaton","year":"2003","journal-title":"Thromb Haemost"},{"key":"R27-11-20210212","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1160\/TH05-01-0033","article-title":"Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease.","volume":"93","author":"Dellas","year":"2005","journal-title":"Thromb Haemost"},{"key":"R28-11-20210212","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1096\/fasebj.14.10.1400","article-title":"A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo.","volume":"14","author":"Guo","year":"2000","journal-title":"FASEB J"},{"key":"R29-11-20210212","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/ijc.2910570520","article-title":"Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model.","volume":"57","author":"Kobayashi","year":"1994","journal-title":"Int J Cancer"},{"key":"R30-11-20210212","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-3-642-59349-9_4","article-title":"Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo.","volume":"162","author":"Magdolen","year":"2003","journal-title":"Recent Results Cancer Res"},{"key":"R31-11-20210212","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1055\/s-0038-1657541","article-title":"Clinical impact of the plasminogen target for therapy.","volume":"78","author":"Schmitt","year":"1997","journal-title":"Thromb Haemost"},{"key":"R32-11-20210212","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/jnci\/94.2.116","article-title":"Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.","volume":"94","author":"Look","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"R33-11-20210212","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/172460080301800309","article-title":"Limited prognostic value of c-erbB-2 compared to uPA and PAI-1 in primary breast carcinoma.","volume":"18","author":"Bouchet","year":"2003","journal-title":"Int J Biol Markers"},{"key":"R34-11-20210212","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/jnci\/91.10.869","article-title":"Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.","volume":"91","author":"Stephens","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"R35-11-20210212","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/bmj.316.7134.829","article-title":"Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer.","volume":"316","author":"Nielsen","year":"1998","journal-title":"BMJ"},{"key":"R36-11-20210212","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1006\/gyno.1994.1313","article-title":"Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy.","volume":"55","author":"Kuhn","year":"1994","journal-title":"Gynecol Oncol"},{"key":"R37-11-20210212","first-page":"2900","article-title":"Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-I in completely resected gastric cancer.","volume":"54","author":"Nekarda","year":"1994","journal-title":"Cancer Res"},{"key":"R38-11-20210212","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1172\/JCI118323","article-title":"Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis and metastasis to lung and liver in an athymic mouse model.","volume":"96","author":"Soff","year":"1995","journal-title":"J Clin Invest"},{"key":"R39-11-20210212","doi-asserted-by":"crossref","first-page":"6939","DOI":"10.1073\/pnas.87.18.6939","article-title":"Plasminogen activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells.","volume":"87","author":"Cajot","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R40-11-20210212","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3109\/02713689509003755","article-title":"Tissue-type plasminogen activator-induced invasion and metastasis of murine melanomas.","volume":"14","author":"Alizadet","year":"1995","journal-title":"Curr Eye Res"},{"key":"R41-11-20210212","first-page":"1445","article-title":"Plasminogen activator inhibitor-1 (PAI-1) gene transfection inhibits the liver metastasis of pancreatic cancer by preventing angiogenesis.","volume":"14","author":"Inoue","year":"2005","journal-title":"Oncol Rep"},{"key":"R42-11-20210212","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.clinbiochem.2004.05.013","article-title":"The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.","volume":"37","author":"Duffy","year":"2004","journal-title":"Clin Biochem"},{"key":"R43-11-20210212","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/172460080602100305","article-title":"Is the urokinase-type plasminogen activator system a reliable prognostic factor in gastric cancer?","volume":"21","author":"Luebke","year":"2006","journal-title":"Int J Biol Markers"}],"container-title":["Pancreas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPA.0b013e31815ac538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:51:26Z","timestamp":1620964286000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006676-200803000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/mpa.0b013e31815ac538","relation":{},"ISSN":["0885-3177"],"issn-type":[{"value":"0885-3177","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}